Smartphone-based fluorescent lateral flow immunoassay platform for highly sensitive point-of-care detection of Zika virus nonstructural protein 1.

Journal: Analytica chimica acta
PMID:

Abstract

Simple, inexpensive, and rapid diagnostic tests in low-resource settings with limited laboratory equipment and technical expertise are instrumental in reducing morbidity and mortality from epidemic infectious diseases. We developed a smartphone-based fluorescent lateral flow immunoassay (LFIA) platform for the highly sensitive point-of-care detection of Zika virus nonstructural protein 1 (ZIKV NS1). An attachment was designed and 3D-printed to integrate the smartphone with external optical and electrical components, enabling the miniaturization of the instrument and reduction in cost and complexity. Quantum dot microspheres were utilized as probes in fluorescent LFIA because of their extremely bright fluorescence signal. This approach can achieve quantitative point-of-care detection of ZIKV NS1 within 20 min. Limits of detection (LODs) in buffer and serum were 0.045 and 0.15 ng mL, respectively. Despite the high structural similarity, a high-level Dengue virus NS1 as interferent showed limited cross-reactivity. Furthermore, this assay was successfully applied to detecte ZIKV NS1 and virions spiked in complex biological samples, indicating its practical application capability. Given its low cost, compact size, and excellent analytical performance, the proposed smartphone-based fluorescent LFIA platform holds considerable potential in rapid and accurate point-of-care detection of ZIKV NS1 and provides new insight into the design and application of molecular diagnostic methods in low-resource settings.

Authors

  • Zhen Rong
    Department of Colorectal and Anal Surgery, Linzi District People's Hospital, Linzi, Shandong, P. R. China.
  • Qiong Wang
    Beijing Meiling Biotechnology Corporation, Beijing, 102600, PR China.
  • Nanxi Sun
    Beijing Institute of Radiation Medicine, Beijing, 100850, PR China.
  • Xiaofei Jia
    Beijing Institute of Radiation Medicine, Beijing, 100850, PR China; College of Life Sciences & Bio-Engineering, Beijing University of Technology, Beijing, 100124, PR China.
  • Keli Wang
    Beijing Institute of Radiation Medicine, Beijing, 100850, PR China; Anhui Medical University, Hefei, Anhui, 230032, PR China.
  • Rui Xiao
    Beijing Institute of Radiation Medicine, Beijing, 100850, PR China; Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing, 100850, PR China. Electronic address: ruixiao203@sina.com.
  • Shengqi Wang
    Beijing Institute of Radiation Medicine, Beijing, 100850, PR China; Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing, 100850, PR China. Electronic address: sqwang@bmi.ac.cn.